

Special Issue

Liver Cancer: Molecular and Translational Insights of Carcinogenesis and Treatments

Message from the Guest Editor

Liver cancer is one of the most prevalent malignancies and a leading cause of cancer-related mortality worldwide. The two main subtypes, hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (ICC), pose significant clinical challenges. To improve clinical outcomes and advance personalized medicine, a more comprehensive understanding of the molecular and cellular mechanisms driving hepatic carcinogenesis is needed, along with the identification of robust diagnostic, prognostic, and predictive biomarkers. This Special Issue invites original research, reviews, and translational studies that explore the molecular and translational aspects of liver cancer. Topics of interest include the molecular and cellular pathogenesis of HCC and ICC, biomarker identification and validation, novel therapeutic targets, advancements in pathology and molecular diagnostics, and innovations in imaging techniques. In addition, submissions addressing the molecular and pathological characteristics of benign and premalignant hepatocellular and biliary tumors, as well as the updated histological and molecular classifications of HCC and ICC, are also welcome.

Guest Editor

Prof. Dr. Joon Hyuk Choi

Department of Pathology, Yeungnam University College of Medicine,
Daegu, Republic of Korea

Deadline for manuscript submissions

28 February 2026



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/243205

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPUS / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).